Emendo Biotherapeutics
Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology.
About
Technology stack
detected 2026-06-13No comments yet. Be the first to share your take.
What does Emendo Biotherapeutics do?
Emendo Biotherapeutics is a genome editing company focused on creating novel genetic medicines and cell therapies for patients suffering from severe diseases. Their approach leverages proprietary protein engineering and selection platforms to generate highly specific and potent CRISPR OMNI nucleases, aiming to overcome limitations of existing gene editing tools.
How much funding has Emendo Biotherapeutics raised?
Emendo Biotherapeutics has raised a total of $61M in funding. The most recent round on record is Series B.
Where is Emendo Biotherapeutics headquartered?
Emendo Biotherapeutics is headquartered in Tel Aviv, Israel.
When was Emendo Biotherapeutics founded?
Emendo Biotherapeutics was founded in 2015.
What industry does Emendo Biotherapeutics operate in?
Emendo Biotherapeutics operates in Healthcare, Genome Editing, CRISPR, Biotech, MedTech, HealthTech.
How many employees does Emendo Biotherapeutics have?
Emendo Biotherapeutics has approximately 41 people on record.